Biotech Insights: Future of GLP-1s, AI's Impact, and Tariffs
ByAinvest
Wednesday, Sep 24, 2025 4:07 pm ET1min read
TNFA--
TNF Pharmaceuticals, Inc. has announced a collaboration with Renova Health to explore the effects of its lead candidate, isomyosamine (MYMD-1), on GLP-1-induced sarcopenia and frailty. The fully funded study will evaluate TNF-α levels in patients receiving GLP-1 agonists Wegovy or Ozempic who show signs of increased inflammation associated with sarcopenia [2]. This trial aims to address a significant issue in GLP-1 therapies, as up to 40% of the total weight lost by GLP-1 patients is lean body mass, including skeletal muscle mass.
Citi Research's Anne Malone and Geoff Meacham recently discussed the future of GLP-1s, the impact of AI on biotech, and potential effects of tariffs. Malone, head of North America Equity Research, and Meacham, U.S. pharma and biotech research analyst, provided insights into the biotech industry's prospects, including the role of AI in drug discovery and development. They also touched on the potential challenges posed by tariffs and how they might impact the industry.
UBS--
Citi Research's Anne Malone and Geoff Meacham discuss the future of GLP-1s, the impact of AI on biotech, and potential effects of tariffs. Malone, head of North America Equity Research, and Meacham, U.S. pharma and biotech research analyst, provide insights on the biotech industry.
UBS has revised its global GLP-1 sales forecast for 2030, slashing it from over $150 billion to $130 billion [1]. The downgrade is attributed to weaker-than-expected data from next-generation assets and compounded product disruptions in the US market. Despite the adjustment, UBS maintains that the GLP-1 and incretin market is one of the most exciting growth drivers in global pharma, projecting a 19% sales CAGR between 2024 and 2030. The obesity treatment segment is expected to see the largest expansion, growing from 4.4 million patients in 2024 to 34 million by 2030.TNF Pharmaceuticals, Inc. has announced a collaboration with Renova Health to explore the effects of its lead candidate, isomyosamine (MYMD-1), on GLP-1-induced sarcopenia and frailty. The fully funded study will evaluate TNF-α levels in patients receiving GLP-1 agonists Wegovy or Ozempic who show signs of increased inflammation associated with sarcopenia [2]. This trial aims to address a significant issue in GLP-1 therapies, as up to 40% of the total weight lost by GLP-1 patients is lean body mass, including skeletal muscle mass.
Citi Research's Anne Malone and Geoff Meacham recently discussed the future of GLP-1s, the impact of AI on biotech, and potential effects of tariffs. Malone, head of North America Equity Research, and Meacham, U.S. pharma and biotech research analyst, provided insights into the biotech industry's prospects, including the role of AI in drug discovery and development. They also touched on the potential challenges posed by tariffs and how they might impact the industry.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet